Semaglutide FDA Approval History: Timeline and Updates
From a diabetes drug to a cardiovascular breakthrough, semaglutide has had one of the most remarkable regulatory journeys in modern pharmaceutical history.
Semaglutide — the active ingredient in Ozempic, Wegovy, and Rybelsus — has transformed the treatment of both type 2 diabetes and obesity. Its FDA approval history reflects a growing body of clinical evidence that has expanded the drug's indications far beyond what was originally envisioned. This article traces every major milestone in semaglutide's regulatory journey.
Early Development: The Science Behind Semaglutide
Semaglutide was developed by Novo Nordisk, the Danish pharmaceutical company that has led GLP-1 receptor agonist development for decades. The drug built upon the company's earlier GLP-1 medications, including liraglutide (Victoza/Saxenda).
The key innovation of semaglutide was its extended half-life. While natural GLP-1 is broken down within minutes, semaglutide's chemical modifications allow it to remain active for approximately one week. This made once-weekly dosing possible — a significant improvement over the daily injections required by earlier GLP-1 drugs.
Semaglutide achieves its long duration through three structural modifications:
- Amino acid substitution: A single amino acid change at position 8 protects against enzymatic degradation by DPP-4
- Fatty acid chain: A C-18 fatty acid chain attached via a linker allows the molecule to bind to albumin in the blood, extending its circulation time
- Additional amino acid change: A modification at position 34 ensures the fatty acid chain attaches at the optimal location
Complete FDA Approval Timeline
Ozempic Approved for Type 2 Diabetes
The FDA approved semaglutide injection (brand name Ozempic) for improving blood sugar control in adults with type 2 diabetes, alongside diet and exercise. Available in 0.5 mg and 1.0 mg doses administered once weekly.
Rybelsus Approved — First Oral GLP-1
The FDA approved semaglutide tablets (brand name Rybelsus) for type 2 diabetes, making it the first oral GLP-1 receptor agonist. Available in 3 mg, 7 mg, and 14 mg daily doses. This was a breakthrough in delivery method, though oral bioavailability remains limited (~1%).
Ozempic Cardiovascular Indication
The FDA approved a label update for Ozempic to include a cardiovascular benefit claim, based on the SUSTAIN-6 trial showing reduced risk of major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.
Wegovy Approved for Weight Management
A landmark moment: the FDA approved semaglutide 2.4 mg injection (brand name Wegovy) for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition. Based on the STEP clinical trial program showing 14.9-17.4% average body weight loss.
Ozempic 2.0 mg Dose Approved
The FDA approved a higher 2.0 mg dose of Ozempic for type 2 diabetes, providing additional blood sugar lowering for patients who needed more glycemic control beyond the original 0.5 mg and 1.0 mg doses.
Wegovy Approved for Adolescents (12+)
Based on the STEP TEENS trial, the FDA expanded Wegovy's approval to include adolescents aged 12 years and older with obesity. The trial showed an average 16.1% reduction in BMI compared to 0.6% with placebo over 68 weeks.
Wegovy Cardiovascular Risk Reduction
A historic approval: the FDA approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and either obesity or overweight. Based on the SELECT trial, this was the first time a weight loss drug received a cardiovascular indication. The trial showed a 20% reduction in major adverse cardiovascular events.
The STEP Clinical Trial Program
The weight loss approval of semaglutide was built on the Semaglutide Treatment Effect in People with Obesity (STEP) program — one of the largest clinical trial programs ever conducted for obesity treatment. Understanding these trials helps explain why the FDA approved Wegovy.
STEP 1: The Foundational Trial
Published in the New England Journal of Medicine in February 2021, STEP 1 enrolled 1,961 adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity, but without diabetes. Key findings:
- Average weight loss of 14.9% of body weight over 68 weeks (vs. 2.4% with placebo)
- 86.4% of participants lost at least 5% of their body weight
- Significant improvements in cardiometabolic risk factors
STEP 2: Diabetes Population
Tested semaglutide 2.4 mg in 1,210 adults with type 2 diabetes and overweight or obesity. Average weight loss was 9.6% — lower than STEP 1 because weight loss tends to be more modest in people with diabetes due to insulin resistance and other metabolic factors.
STEP 3: Intensive Behavioral Therapy
Combined semaglutide with intensive behavioral therapy (30 counseling sessions over 68 weeks). Average weight loss was 16.0%, suggesting that combining medication with behavioral support enhances outcomes.
STEP 4: Sustained Treatment Effects
Examined what happens when patients switch from semaglutide to placebo after initial weight loss. Those who continued semaglutide maintained their weight loss, while those switched to placebo regained weight — demonstrating that ongoing treatment is needed for sustained benefits.
STEP 5: Two-Year Data
The longest trial, running 104 weeks, showed sustained weight loss of 15.2% at two years. This was crucial for demonstrating long-term efficacy and helped address concerns about durability.
The SELECT Trial: Cardiovascular Breakthrough
The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial was a game-changer. This 17,604-patient trial examined whether semaglutide could reduce cardiovascular events in people with obesity and established cardiovascular disease — but without diabetes.
Results, published in November 2023, showed a 20% reduction in major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) over a mean follow-up of 39.8 months. This was groundbreaking because it demonstrated that treating obesity itself — not just diabetes — reduces cardiovascular risk.
The SELECT trial's significance cannot be overstated. It fundamentally shifted how the medical community views obesity treatment, moving it from a cosmetic concern to a cardiovascular intervention.
Ongoing Research and Potential Future Approvals
Novo Nordisk continues to study semaglutide for additional indications. Areas of active research include:
- Metabolic-associated steatohepatitis (MASH): Semaglutide has shown promise in reducing liver fat and inflammation in patients with fatty liver disease
- Heart failure with preserved ejection fraction (HFpEF): Studies show improvements in heart failure symptoms and functional capacity
- Chronic kidney disease: The FLOW trial demonstrated renal protective effects
- Alzheimer's disease and cognitive decline: Early research suggests potential neuroprotective effects, with clinical trials underway
- Obstructive sleep apnea: The STEP-OSA trials showed significant reductions in sleep apnea severity
- Higher-dose oral semaglutide: Novo Nordisk is developing a higher-dose oral formulation (25 mg and 50 mg) for weight management
Drug Shortage and Compounding Status
Due to unprecedented demand, both Ozempic and Wegovy have been on the FDA Drug Shortage List for significant periods since 2022. This shortage status has enabled compounding pharmacies to produce compounded semaglutide, providing more affordable access for many patients.
The shortage situation has created a complex regulatory landscape, with ongoing questions about when shortages will be fully resolved and what will happen to the compounding market when they are. For patients, understanding the difference between 503A and 503B pharmacies is important when considering compounded options.
Global Regulatory Approvals
While this article focuses on FDA (U.S.) approvals, semaglutide has been approved in numerous countries worldwide:
- European Medicines Agency (EMA): Approved Ozempic in 2018 and Wegovy in 2022
- Health Canada: Approved for both diabetes and weight management
- UK MHRA: Approved with NICE guidance for NHS prescribing
- Australia TGA: Approved for diabetes; weight management approval followed
- Japan PMDA: Approved for type 2 diabetes
To learn more about whether semaglutide might be right for you, visit our how it works page or explore available treatment options.
Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice. FDA approval status and indications may change. Always consult with a licensed healthcare provider before starting or changing any medication. Visit FDA.gov for the most current drug approval information.
Explore GLP-1 Treatment Options
Connect with licensed providers who can help determine the right GLP-1 medication for your needs.
Get Started TodayMore on FDA and legal
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).